Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Accenture
Julphar
Merck
Farmers Insurance
US Army

Generated: July 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,138,456

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,138,456 protect, and when does it expire?

Patent 9,138,456 protects CUBICIN RF and is included in one NDA.

This patent has forty patent family members in twenty-seven countries.

Summary for Patent: 9,138,456
Title:Lipopeptide compositions and related methods
Abstract: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.
Inventor(s): O'Connor; Sandra (Hudson, NH), Sun; Sophie (Lexington, MA), Naik; Gaauri (Cambridge, MA)
Assignee: Cubist Pharmaceuticals LLC (Kenilworth, NJ)
Application Number:14/096,346
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,138,456
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 9,138,456
Patent Claim Types:
see list of patent claims
Composition; Formulation; Process;

Drugs Protected by US Patent 9,138,456

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cubist Pharms Llc CUBICIN RF daptomycin POWDER;INTRAVENOUS 021572-003 Jul 6, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Deloitte
McKinsey
QuintilesIMS
Queensland Health
Fuji

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.